Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Historical Acquisition Tree
Alternative names
Key: Viracta Therapeutics, Inc. (0) Acquired (2)
cytarabine (cytosar-u) (2 trials)
vosaroxin (12 trials)
Key: Viracta Therapeutics, Inc. (3) Acquired (3)
azacitidine (vidaza) (1 trial)
decitabine (dacogen) (1 trial)
Nanatinostat (3 trials)
pembrolizumab (keytruda) (1 trial)
sns-062 (1 trial)
valganciclovir (Valcyte) (3 trials)
bms 387032 (2 trials)
sns-314 (1 trial)
Lymphoproliferative Disorders (Phase 2)
Neoplasms (Phase 2)
Trials (19 total)
Trial APIs (10 total)